Switch theme
Sign up to access all valuation multiples
Sun Pharmaceuticals Industries Ltd is India's generic pharmaceutical manufacturing company. The company’s substantial markets are the U.S. and India to make up the majority of revenue. The remaining is spread across both emerging and developed markets. In addition to generics, the company also produces and distributes name-brand formulas to specific geographies. It maintains manufacturing and research and development facilities globally to serve its markets but is majorly based in India.
1993
19.5K+
LTM Revenue $6.2B
LTM EBITDA $1.8B
$44.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sun Pharma has a last 12-month revenue (LTM) of $6.2B and a last 12-month EBITDA of $1.8B.
In the most recent fiscal year, Sun Pharma achieved revenue of $6.1B and an EBITDA of $1.9B.
Sun Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sun Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.2B | XXX | $6.1B | XXX | XXX | XXX |
| Gross Profit | $4.9B | XXX | $4.8B | XXX | XXX | XXX |
| Gross Margin | 79% | XXX | 79% | XXX | XXX | XXX |
| EBITDA | $1.8B | XXX | $1.9B | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 32% | XXX | XXX | XXX |
| EBIT | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $1.4B | XXX | $1.3B | XXX | XXX | XXX |
| Net Margin | 22% | XXX | 21% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sun Pharma's stock price is INR 1678 (or $20).
Sun Pharma has current market cap of INR 4.03T (or $47.1B), and EV of INR 3.78T (or $44.3B).
See Sun Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $44.3B | $47.1B | XXX | XXX | XXX | XXX | $0.57 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sun Pharma has market cap of $47.1B and EV of $44.3B.
Sun Pharma's trades at 7.4x EV/Revenue multiple, and 23.8x EV/EBITDA.
Equity research analysts estimate Sun Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sun Pharma has a P/E ratio of 34.4x.
See valuation multiples for Sun Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $47.1B | XXX | $47.1B | XXX | XXX | XXX |
| EV (current) | $44.3B | XXX | $44.3B | XXX | XXX | XXX |
| EV/Revenue | 7.1x | XXX | 7.4x | XXX | XXX | XXX |
| EV/EBITDA | 24.9x | XXX | 23.8x | XXX | XXX | XXX |
| EV/EBIT | 29.7x | XXX | 31.5x | XXX | XXX | XXX |
| EV/Gross Profit | 9.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 34.4x | XXX | 38.0x | XXX | XXX | XXX |
| EV/FCF | 36.6x | XXX | 33.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSun Pharma's last 12 month revenue growth is 9%
Sun Pharma's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Sun Pharma's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sun Pharma's rule of X is 52% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sun Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | 41% | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 52% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sun Pharma acquired XXX companies to date.
Last acquisition by Sun Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Sun Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sun Pharma founded? | Sun Pharma was founded in 1993. |
| Where is Sun Pharma headquartered? | Sun Pharma is headquartered in India. |
| How many employees does Sun Pharma have? | As of today, Sun Pharma has 19.5K+ employees. |
| Is Sun Pharma publicy listed? | Yes, Sun Pharma is a public company listed on NSE. |
| What is the stock symbol of Sun Pharma? | Sun Pharma trades under SUNPHARMA ticker. |
| When did Sun Pharma go public? | Sun Pharma went public in 1995. |
| Who are competitors of Sun Pharma? | Similar companies to Sun Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Sun Pharma? | Sun Pharma's current market cap is $47.1B |
| What is the current revenue of Sun Pharma? | Sun Pharma's last 12 months revenue is $6.2B. |
| What is the current revenue growth of Sun Pharma? | Sun Pharma revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Sun Pharma? | Current revenue multiple of Sun Pharma is 7.1x. |
| Is Sun Pharma profitable? | Yes, Sun Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sun Pharma? | Sun Pharma's last 12 months EBITDA is $1.8B. |
| What is Sun Pharma's EBITDA margin? | Sun Pharma's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Sun Pharma? | Current EBITDA multiple of Sun Pharma is 24.9x. |
| What is the current FCF of Sun Pharma? | Sun Pharma's last 12 months FCF is $1.2B. |
| What is Sun Pharma's FCF margin? | Sun Pharma's last 12 months FCF margin is 19%. |
| What is the current EV/FCF multiple of Sun Pharma? | Current FCF multiple of Sun Pharma is 36.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
